Akzo Nobel's net income for 1996 is expected to be around the same asthat achieved in 1995, said Cees van Lede, chairman of the group, in his New Year speech. "We will not remember 1996 as an easy year. The scientific dispute surrounding the pill and the slow start of the economy in Europe kept us in suspense for a long time," he commented. He suggested that economic prospects in 1997 are in the group's favor, with continued, albeit moderate, growth and low inflation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze